Full text

Turn on search term navigation

© 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Background

The oral anti‐janus kinase 1 inhibitor upadacitinib has shown a good efficacy–safety profile in the treatment of moderate‐to‐severe atopic dermatitis (AD) in clinical trials; however, few data from real clinical practice have been published so far.

Objectives

To evaluate the efficacy and safety of upadactinib in clinical practice.

Methods

An observational and multicentric study was conducted. Inclusion criteria consisted of patients who had previously received upadacitinib in the clinical trial M19‐850 and continued treatment with upadacitinib (15 mg or 30 mg) under daily clinical practice conditions for 12 months. Demographic data, characteristics of AD, treatment response and adverse events were recorded. Preliminary results at 24‐week follow‐up are herein presented.

Results

A total of 26 patients (61.54% males, mean age: 35.58 years) were included in the study; of these, 92.31% received upadacitinib 30 mg at baseline. At 24 weeks, mean values of Eczema Area and Severity Index and body surface area were 2.26 and 2.37%, respectively, 82.35% of the patients reached the Investigator's Global Assessment 0/1 and the mean value of peak pruritus numerical rating scale was 1.74. Adverse events were present in 19.23% of the cases, causing one definitive treatment interruption (due to herpes zoster) and two temporary treatment discontinuations (due to temporary elevation of creatine kinase).

Conclusions

These data support the maintenance of the efficacy of upadacitinib at 24‐week posttrial follow‐up, with no unexpected safety concerns. More real‐world data are needed to confirm these results.

Details

Title
Observational 24‐week study to assess clinical response to upadacitinib posttrial in patients with moderate‐to‐severe atopic dermatitis
Author
Batalla, Ana 1   VIAFID ORCID Logo  ; Suh‐Oh, Hae Jin 1 ; Carretero Hernández, Gregorio 2 ; Miquel‐Miquel, Javier 3 ; Botella‐Estrada, Rafael 4 ; Martorell‐Calatayud, Antonio 5   VIAFID ORCID Logo  ; Sanz‐Motilva, Virginia 5 ; Figueras‐Nart, Ignasi 6 ; Flórez, Angeles 1 

 DIPO Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS‐UVIGO, Pontevedra‐Vigo, Spain 
 Dermatology Department, Hospital Universitario de Gran Canaria Dr. Negrín, Gran Canaria, Spain 
 Dermatology Department, Hospital Universitario Arnau de Vilanova, Valencia, Spain 
 Dermatology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain 
 Dermatology Department, Hospital de Manises, Valencia, Spain 
 Dermatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain 
Pages
571-575
Section
SHORT REPORTS
Publication year
2023
Publication date
Sep 1, 2023
Publisher
John Wiley & Sons, Inc.
ISSN
27686566
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3090616299
Copyright
© 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.